JPMorgan Chase & Co. Purchases 194,480 Shares of Harrow, Inc. (NASDAQ:HROW)

JPMorgan Chase & Co. grew its holdings in Harrow, Inc. (NASDAQ:HROW) by 443.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 238,367 shares of the company’s stock after acquiring an additional 194,480 shares during the quarter. JPMorgan Chase & Co. owned 0.67% of Harrow worth $10,717,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Principal Financial Group Inc. acquired a new stake in shares of Harrow in the third quarter worth $329,000. Virtu Financial LLC acquired a new stake in Harrow in the 3rd quarter worth about $271,000. Geode Capital Management LLC increased its stake in Harrow by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock worth $32,500,000 after buying an additional 3,960 shares in the last quarter. Barclays PLC raised its position in shares of Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company’s stock valued at $2,365,000 after buying an additional 39,506 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Harrow during the third quarter worth approximately $487,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on HROW. B. Riley lowered their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. Lake Street Capital increased their price target on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Finally, Craig Hallum raised their price objective on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 4th.

Harrow Trading Up 1.4 %

NASDAQ:HROW opened at $36.67 on Monday. Harrow, Inc. has a 12-month low of $9.13 and a 12-month high of $59.23. The firm has a market cap of $1.31 billion, a P/E ratio of -39.01 and a beta of 0.72. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The stock’s 50 day simple moving average is $39.58 and its 200-day simple moving average is $38.48.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.